These findings support the development of strategies attempting to increase α-KG levels by inhibition of BCAT1 to inhibit leukemic stem cells and thus to improve the outcome of AML patients, expressing high levels of BCAT1, not associated with TET2 or IDH mutations. This evidence concerns the gene TET2 and acute myeloid leukemia.